Yousif Capital Management LLC Buys 1,318 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Yousif Capital Management LLC raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 43,437 shares of the biopharmaceutical company’s stock after purchasing an additional 1,318 shares during the period. Yousif Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $943,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of CPRX. GAMMA Investing LLC grew its holdings in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 579 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Catalyst Pharmaceuticals by 65.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 35,334 shares of the biopharmaceutical company’s stock valued at $857,000 after purchasing an additional 13,915 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in Catalyst Pharmaceuticals during the first quarter valued at about $211,000. Cambridge Investment Research Advisors Inc. bought a new stake in Catalyst Pharmaceuticals during the first quarter valued at about $484,000. Finally, Retirement Guys Formula LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter valued at about $231,000. Institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 115,000 shares of the stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.28, for a total transaction of $2,332,200.00. Following the completion of the transaction, the insider directly owned 949,663 shares of the company’s stock, valued at approximately $19,259,165.64. This represents a 10.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David S. Tierney sold 26,000 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $20.20, for a total value of $525,200.00. Following the transaction, the director directly owned 379,620 shares of the company’s stock, valued at approximately $7,668,324. The trade was a 6.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 243,970 shares of company stock valued at $4,927,241 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the subject of several recent research reports. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, October 12th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $33.20.

Catalyst Pharmaceuticals Stock Up 2.0%

NASDAQ CPRX opened at $21.43 on Wednesday. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 0.84 and a beta of 0.79. The business has a 50-day moving average price of $20.29 and a 200-day moving average price of $21.89. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share for the quarter. The firm had revenue of $53.11 million during the quarter. Catalyst Pharmaceuticals had a return on equity of 40.78% and a net margin of 37.36%. Research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current fiscal year.

Catalyst Pharmaceuticals declared that its Board of Directors has approved a share repurchase plan on Wednesday, October 1st that permits the company to buyback $200.00 million in shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 8.3% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.